Asmalon

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Asmalon

Quick Facts

Property Description
Active ingredient Choline Theophyllinate (Oxtriphylline)
Form Tablet, Sustained-Release Tablet, Solution, Injection
Pharmacological Class Methylxanthine Bronchodilator
Common Use Management of reversible airway obstruction
Origin Synthetic Derivative cdot Pharmaceutical Salt Complex
Distinctive Feature Salt complex for optimized delivery of Theophylline

What Type of Medicine is Asmalon and What is its Purpose?

Asmalon is a systemic prescription medication classified as a bronchodilator and antiasthmatic drug, belonging to the methylxanthine pharmacological class. This type of classification is clinically recognized for its utility in respiratory management. The medicine's primary role is to induce bronchodilation, which is the physiological widening of the airways to increase air movement into and out of the lungs. Methylxanthines are used for promoting airway smooth muscle relaxation in obstructive diseases.

Its general purpose is to provide maintenance therapy for managing conditions characterized by constricted airways, such as managing chronic breathlessness and reducing the frequency of chest tightness associated with reversible obstructive airway disease. The systemic nature of this medication, acting via the bloodstream, differentiates it from localized inhalational treatments.


Active Ingredient and Chemical Classification of Asmalon

The active ingredient in Asmalon is Choline Theophyllinate, a compound also recognized by the synonym Oxtriphylline. Choline Theophyllinate is a synthetic derivative formulated as a pharmaceutical salt complex, created by chemically combining the active drug Theophylline with Choline. This unique structure is designed to enhance the stability and absorption of the Theophylline component, which is the core xanthine derivative responsible for the bronchodilating effect.

The use of this specific salt complex is a distinctive feature intended to improve gastrointestinal tolerability compared to pure Theophylline. Theophylline's bronchodilator properties are recognized for therapeutic use.


Available Forms and Administration Routes

Asmalon is manufactured in multiple dosage forms to accommodate various therapeutic needs and routes of delivery. The drug is most commonly available as oral tablets and specialized sustained-release tablets for ingestion. Furthermore, it is produced as an oral solution and an injectable solution (ampoules), which allows for parenteral (intravenous) administration when a rapid or comprehensive systemic effect is required in a controlled medical setting.

Regulatory References

  1. Theophylline - NIH DailyMed Monograph

What side effects are possible with Asmalon?

Possible Side Effects and Safety Information

The safety profile of Asmalon (Choline Theophyllinate), an official methylxanthine bronchodilator, is structured by governmental regulatory documents to highlight effects primarily related to the concentration of the active drug, Theophylline, in the bloodstream. The occurrence and severity of adverse reactions are highly dose-dependent.

Official Adverse Reaction Scope

Adverse effects are categorized by the physiological systems affected, including Gastrointestinal disorders (e.g., nausea, vomiting, epigastric pain), Nervous system disorders (e.g., headache, tremor, insomnia), and Cardiac disorders (e.g., tachycardia, palpitations).

Frequency Classification Examples of Officially Listed Reactions
Common Nausea, Vomiting, Headache, Insomnia, Restlessness
Rare Generalized Seizures (Convulsions), Ventricular Arrhythmias

Serious Safety Considerations

Regulatory agencies document Serious Adverse Reactions (SARs) that may occur, often associated with high systemic concentrations. These include life-threatening Ventricular Arrhythmias, generalized Seizures, and Vascular Collapse. These serious effects may manifest without being preceded by less severe common symptoms.

Population and Exposure Notes

The drug's clearance is explicitly documented to be significantly reduced in specific populations, including older adults and patients with underlying conditions such as Hepatic Impairment or Congestive Heart Failure. This reduction in clearance increases the risk of drug accumulation and toxicity. Furthermore, official labeling restricts its use in conditions such as active peptic ulcer disease or an untreated seizure disorder. The safety profile is critically dependent on serum concentration, making dose adjustments necessary in the context of conditions like febrile illness, which can reduce clearance.

Overdose and Emergency Response

Overdose and when to seek help

An overdose occurs when a dose of medication significantly exceeds the recommended amount, leading to toxic effects in the body. The severity of an overdose can range from mild effects to life-threatening complications, especially in cases of chronic exposure to high doses.

Documented Overdose Presentations

Overdose presentations are primarily characterized by significant changes across the cardiovascular, neurological, and gastrointestinal systems. Symptoms frequently reported in cases of acute overdose include:

  • Cardiovascular: Extremely rapid heart rate (tachycardia), irregular heartbeat (ventricular arrhythmias), and palpitations. Changes in blood pressure, which may include initial hypertension followed by a decrease.
  • Neurological: Seizures, tremors (shaking), severe agitation, restlessness, and confusion.
  • Gastrointestinal and Metabolic: Persistent and severe vomiting, nausea, abdominal pain, and significant metabolic disturbances such as high blood sugar (hyperglycemia) and dangerously low potassium levels (hypokalemia).

Seeking Immediate Medical Attention

An overdose of Asmalon is considered a medical emergency. Immediate and urgent medical help is required if any of the following severe signs are observed:

  • Seizures or loss of consciousness.
  • Difficulty breathing or cessation of breathing.
  • Rapid, pounding, or irregular heartbeat, or chest pain.
  • Persistent vomiting or uncontrollable tremors.

Emergency Response

If an overdose is suspected, immediately call emergency services and seek guidance from a poison control center. Do not attempt to induce vomiting unless specifically advised to do so by a medical professional. Provide the emergency responders with all available information about the amount taken and the time of ingestion.

Supportive care in a medical setting focuses on managing life-threatening symptoms, stabilizing heart rhythm, correcting metabolic imbalances, and potentially using activated charcoal to limit drug absorption.

Therapeutic Uses of Asmalon

What Asmalon Treats: Main Uses and Benefits

Asmalon is applied in addressing conditions characterized by periods of heightened symptoms, playing a role in the long-term management of Bronchial Asthma and Chronic Obstructive Pulmonary Disease (COPD). It is considered relevant in conditions presenting with systemic or localized discomfort such as Chronic Bronchitis and Emphysema. The primary function is to provide supportive relief for symptoms related to physical discomfort.

This medication is commonly used to help with the symptoms of chronic lung diseases. It may assist with managing the symptom cluster of wheezing, persistent coughing, and shortness of breath (dyspnea) that arise from tightened airways. The practical benefit helps ease the overall symptom burden, particularly during recurrent or episodic manifestations, such as those associated with Nocturnal Asthma.

By contributing to improved comfort during symptomatic periods, the medication provides supportive relief when symptoms interfere with routine activities.

“These types of medications are generally used to stabilize and manage symptoms that interfere with daily comfort.”


Quick Fact: Relief for Airflow Restriction
Primary Therapeutic Use Maintenance therapy for conditions involving episodic or fluctuating manifestations in COPD and Asthma.
Core Symptom Addressed Wheezing, shortness of breath, and chest tightness.
Patient Benefit Supports easing breathing and reducing the frequency of recurrent episodes.

Regulatory References

  1. NIH MedlinePlus overview of Theophylline

Eligibility and Restrictions for Use

Who can and cannot use Asmalon?

This section describes the official population eligibility and non-eligibility for Asmalon, based strictly on government regulatory documents.

Eligibility Status Populations and Conditions
Use is Contraindicated Individuals with documented hypersensitivity to xanthine derivatives (theophylline, aminophylline) or to any of the product's components. Infants under 6 months of age [Source: HPRA, FDA].
Conditional/Restricted Use Hepatic Impairment (liver disease) or Congestive Heart Failure: Clearance is reduced by 50% or more, requiring specific regulatory monitoring. Older adults gt 60 years: Reduced clearance necessitates cautious use [Source: FDA, SPS-NHS].
Age-Related Status Documentation from Regulators
Infants lt 6 months Contraindicated.
Children lt 6 years Not recommended for certain prolonged-release dosage forms; suitability depends on formulation [Source: HPRA].
Adults Generally eligible outside of specific contraindications.

Comorbidity-Based Restrictions Use requires extreme caution and monitoring in patients with a history of seizure disorders, active peptic ulcer disease, or significant cardiac arrhythmias [Source: FDA]. Eligibility is also restricted by acute states that reduce clearance, such as severe sepsis or sustained fever [Source: FDA]. During pregnancy, the medicine is classified as Category C (FDA), and it is secreted in breast milk, defining a conditional use status that requires documented risk assessment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation on Asmalon identifies specific drug interaction domains rooted in both its metabolism and its effects on the heart's electrical system.

Pharmacokinetic Interactions (Metabolism and Transport)

Asmalon is a substrate for the Cytochrome P450 3A4 (CYP3A4) enzyme, which is responsible for its metabolism, and is also affected by the P-glycoprotein (P-gp) transport system. Co-administration with other medicines can alter the concentration of Asmalon in the body.

Interacting Product Category Official Regulatory Instruction
Strong CYP3A4 Inhibitors (e.g., Itraconazole, Ketoconazole, Clarithromycin) Require a dose reduction of Asmalon and monitoring due to potential for increased exposure.
Strong CYP3A4 Inducers (e.g., Rifampin, Carbamazepine, Phenytoin) Co-administration is contraindicated due to a predicted significant reduction in Asmalon exposure, leading to loss of intended effect.
P-glycoprotein (P-gp) Inhibitors (e.g., Verapamil, Quinidine) May increase systemic exposure; monitoring is necessary.

Pharmacodynamic Interactions (Additive Effects)

Official labeling mandates caution or avoidance of combinations that may result in an increased risk of specific adverse effects. Co-administration is contraindicated with other medicinal products known to significantly prolong the QT interval (e.g., Class IA and Class III antiarrhythmics) due to the risk of additive cardiac repolarization effects.

Interactions with Other Products

Interactions with certain dietary supplements, such as Ginseng, have been documented to potentially reduce Asmalon concentration, necessitating professional monitoring.

Mechanism of Action

Asmalon functions as a selective beta2-adrenergic receptor agonist, primarily targeting receptors expressed on the smooth muscle cells of the bronchial tree. Upon administration, the drug binds to and activates these G-protein coupled receptors, initiating an intracellular signaling cascade. Receptor occupancy leads to the activation of the associated stimulatory G-protein ( Gs), which in turn activates the membrane-bound enzyme, adenylyl cyclase.

Adenylyl cyclase catalyzes the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP), causing a transient increase in the intracellular concentration of this second messenger. Elevated cAMP levels result in the activation of protein kinase A (PKA). PKA subsequently phosphorylates specific intracellular proteins, ultimately leading to a reduction in the myocyte's intracellular calcium concentration. This reduction in free ionic calcium levels drives the relaxation of bronchial smooth muscle fibers. The resulting physiological consequence at the system level is an increase in the diameter of the airways, modulating pulmonary airflow resistance.

Dosage and Administration Information

This section provides the instructions for using the drug for the Metered-Dose Inhaler (MDI) formulation.

Official Administration Guidelines

Instruction Category Details
Route of Administration Oral Inhalation.
Dosing Schedule 100 or 200 mcg (1 or 2 inhalations) as needed, repeated every 4 to 6 hours. For prevention of exercise-induced symptoms, 2 inhalations are taken 15 to 30 minutes before exertion.
Frequency Constraints Administration is on an as-needed basis, with a maximum frequency of one dose every 4 hours. Do not increase the dose or frequency if the usual effect is diminished.
Age-Group Rules The standard regimen applies to adults and pediatric patients aged 4 years and older. Dosage for prevention in children aged 4+ may be 1 or 2 inhalations 15 to 30 minutes before exercise.

Preparation and Procedural Steps

The device must be prepared and used according to the following sequence to ensure proper delivery of the medicine:

  1. Priming: Before initial use, or if the inhaler has not been used for several days or has been dropped, remove the cap, shake well, and release four test sprays into the air away from the face.
  2. Administration: Remove the cap and shake the inhaler well. Breathe out fully, then place the mouthpiece into the mouth and close the lips firmly around it.
  3. Inhalation: Press down on the canister while breathing in slowly and deeply (over 3 to 5 seconds). Remove the inhaler from the mouth.
  4. Hold Breath: Hold your breath for approximately 10 seconds or for as long as possible, then breathe out slowly.
  5. Repeat Doses: If a second puff is directed, wait one minute between puffs and repeat steps 2 through 4.
  6. Cleaning: The plastic actuator must be cleaned with warm water and allowed to air-dry completely at least once a week to prevent blockage.

Following these administration and procedural steps ensures the proper use of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Asmalon

Evidence for Use in Bronchial Asthma

Research explored Asmalon (Choline Theophyllinate) in studies involving individuals with conditions characterized by fluctuating or episodic manifestations of asthma, including those where symptoms may vary in intensity, such as during the nighttime (nocturnal asthma). The research primarily examined how symptoms change over time using study designs like randomized controlled trials (RCTs). These studies monitored outcomes over defined time intervals.

Research examined outcomes related to physical discomfort and outcomes reflecting daily functioning. Specifically, studies monitored functional outcomes, such as the Forced Expiratory Volume in One Second (FEV1), and patient-reported outcomes describing perceived discomfort. Some trials described patterns observed in the studies where the measurements of FEV1 in the morning differed when compared to a non-active treatment. Research also describes how symptoms evolved in the observed populations, where patient-reported symptoms were monitored to change. Overall, evidence contributes to the broader evidence landscape by describing short-term symptom patterns related to this condition.

Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD)

Asmalon was evaluated in individuals with conditions marked by functional limitations, specifically those with stable Chronic Obstructive Pulmonary Disease (COPD). The evidence often consists of systematic reviews and meta-analyses, which pool data from multiple randomized, placebo-controlled trials. Studies explored changes measured in pulmonary function metrics, such as FEV1 and Forced Vital Capacity (FVC), over defined time intervals. Data show patterns related to measured lung function that were examined in the groups receiving the compound in some of these trials.

What is Still Uncertain About Asmalon Research

Evidence quality varies across studies, and there are several research limitation frames that apply to the current evidence base. Comparative evidence is lacking against many newer, standard treatments, making the current role of the compound uncertain in some modern clinical contexts. Long-term studies are not fully established, particularly for major outcomes like overall survival or major clinical events, where findings were mixed across observational cohorts. Research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Theophylline and mortality in COPD: a meta-analysis of cohort studies
  2. NIH MedlinePlus overview of Theophylline

Frequently Asked Questions (FAQ)

Common questions about Asmalon (FAQ)


Q: What happens if I miss a dose of Asmalon?

If a dose is missed, official patient information for similar medications with a fixed daily schedule states that taking extra medicine to make up for a missed dose is not recommended. The guidance is to generally continue with the next scheduled dose at the regular time. This approach helps to avoid increasing the dose or frequency beyond what is directed.


Q: Can Asmalon be used by children, and if so, what is the youngest age mentioned in official documents?

Regulatory documents indicate that the standard administration regimen for the metered-dose inhaler formulation applies to pediatric patients aged 4 years and older. Determining suitability for any patient population requires the assessment of a healthcare provider.


Q: What is the official guidance regarding Asmalon and alcohol consumption?

Official information documents that the body's process for eliminating the active drug, Theophylline, may be slower in patients with chronic alcoholism, especially if there is existing liver disease. This reduced clearance could lead to increased exposure. General safety advice often notes caution with alcohol, as it may potentially intensify certain adverse effects such as dizziness.


Q: Can Asmalon be taken with or without food, according to the official instructions?

For the immediate-release oral tablet formulation of the active ingredient, official labeling describes that taking the medicine with food or antacids does not usually cause clinically significant changes in how the drug is absorbed by the body. However, specific instructions can vary depending on the exact form of Asmalon being used.


Q: Are there known lifestyle factors that can affect how well Asmalon works?

Yes, regulatory documents note that certain factors can change how quickly the body processes the medication. For example, the drug's clearance is documented as being shorter in people who smoke cigarettes or marijuana. Clearance is also significantly reduced in patients with a sustained high fever, which is a factor that may be considered when determining dosing.


Q: Why is Asmalon sometimes described as a 'maintenance' therapy?

Official documents classify Asmalon as being indicated for the chronic treatment of conditions involving constricted airways. The active drug is described as having both a primary effect of relaxing the airway muscles (bronchodilation) and additional effects that suppress the airways’ response to stimuli. This role of managing a condition over time is consistent with its classification as a maintenance therapy.


Q: Are there specific warning signs I should look for when starting Asmalon?

Official patient information lists several symptoms that are documented to require reporting to a healthcare provider if they are severe or persistent. These include continued vomiting, ongoing headache, difficulty sleeping, or the presence of tremors. It is noted that rare, serious safety issues like seizures or irregular heartbeats may potentially appear without any preceding common symptoms.


Q: Can Asmalon be split or crushed, or must it be swallowed whole?

For the extended-release oral tablet formulations, official regulatory instructions specifically state that the tablet must be swallowed whole. It is noted that it should not be broken, crushed, or chewed, as this can affect the way the medicine is released into the body.


Q: Do you take Asmalon every day, or only when needed?

This depends on the specific formulation being used, as Asmalon is available in multiple forms. The metered-dose inhaler formulation is described in official documents as being administered on an as-needed basis for symptoms. However, certain oral formulations used for chronic conditions may require taking the medicine at the same time each day to maintain a stable level in the blood.


Q: How quickly does Asmalon start to work after the first dose?

Pharmacokinetic data from clinical studies on the immediate-release form of the active ingredient indicate that the peak concentration in the blood may be reached about 1 to 2 hours after a single oral dose. Bronchodilation is generally described as occurring once the drug reaches a specific concentration range in the bloodstream.


Q: How long does the effect of one dose of Asmalon typically last?

The half-life of the active drug, which is related to the duration of its effect, is documented to vary significantly between individuals. The mean half-life in non-smoker adults is cited in some studies as approximately 8 to 9 hours, though individual factors like age or underlying health conditions can result in a shorter or longer duration.


Q: Is it true that Asmalon is only for temporary relief?

No, official product information states that the medicine's general purpose is to provide maintenance therapy for the long-term management of conditions characterized by constricted airways. This chronic role differs from medications used exclusively for immediate or temporary relief.


Q: What is the difference between Asmalon and a 'rescue' inhaler (assuming Asmalon is not an inhaler)?

Official documentation classifies Asmalon as a systemic medication intended for maintenance therapy for chronic conditions. This role is distinct from the clinical role of 'rescue' inhalers, which are generally used for the rapid treatment of acute symptoms, a use that is not indicated for Asmalon.


Q: Why might a doctor stop prescribing Asmalon to a patient?

Official documents list specific patient conditions that restrict use, such as having an untreated seizure disorder or an active peptic ulcer disease. Furthermore, official guidance mandates monitoring and potential discontinuation if a patient experiences certain serious adverse events, like ventricular arrhythmias or seizures.


Q: Does Asmalon affect blood sugar levels?

High blood sugar, referred to as hyperglycemia, is listed in patient information as a potential side effect associated with the active ingredient, Theophylline. Official guidance is that all individuals with underlying metabolic conditions should discuss potential drug effects with their provider.


Q: Is the sensation of feeling shaky a common side effect of Asmalon?

Yes, the sensation of feeling shaky, medically known as tremors or muscle twitching, is listed as a common potential side effect associated with the active ingredient. This effect is generally related to the drug's concentration in the bloodstream.


Q: What does the FDA / EMA official warning label say about Asmalon?

Official safety documents highlight the risk of Serious Adverse Reactions (SARs), including life-threatening ventricular arrhythmias (a type of irregular heartbeat) and generalized seizures. These serious effects are often associated with high drug concentrations and may potentially occur without being preceded by common symptoms.


Q: Can Asmalon cause issues with heart rhythm or palpitations?

Yes, official safety information lists tachycardia (a rapid heart rate) and palpitations (the feeling of a pounding or racing heart) as potential effects. More serious, rare cardiac issues like ventricular arrhythmias are also documented as a potential adverse reaction.


Q: Is it okay to drive or operate machinery while using Asmalon?

Official patient information advises that caution should be exercised when engaging in activities that require full mental focus, such as driving or operating machinery. This advice is provided because certain potential adverse reactions, like dizziness, may potentially impair a person's ability to safely perform these activities.


Q: What evidence exists about Asmalon's use in combination with other treatments for the same condition?

Laboratory and human data suggest that the active drug may act synergistically, meaning it has an additive benefit when combined with other types of bronchodilators, such as beta-agonists. Official warnings are in place concerning co-administration with other methylxanthine drugs or other specific medications.


Q: Are there any interactions between Asmalon and common vitamin supplements?

Official documentation notes that interactions can occur with certain non-prescription products, providing the example of the supplement Ginseng potentially reducing Asmalon concentration. Official guidance recommends that all patients discuss all supplements, including vitamins, with a healthcare provider.


Q: Does Asmalon have different effects on adults compared to older adults?

Official documents explicitly state that the drug’s clearance from the body is significantly reduced in older adults (aged 55 and over). This difference increases the risk of the drug accumulating to potentially toxic levels, which often means that a lower maximum daily dosage may be appropriate for this age group compared to younger adults.


Q: What are the typical results seen in the research studies for Asmalon?

Clinical studies have described patterns of change in measured lung function, specifically noting that measurements of FEV1 (Forced Expiratory Volume in One Second) in the morning differed when compared to a non-active treatment. Patient-reported outcomes describing discomfort were also monitored to change over time in observed populations during the trials.

How should Asmalon be stored and disposed of?

The storage and disposal of Asmalon must strictly adhere to the requirements listed on the official regulatory labeling and patient information to ensure product stability and safety.

Storage Requirements

  • Temperature and Protection: The medicine must be stored at the temperature specified on the package insert, typically within controlled room temperature ranges. Protection from light and moisture is required; the container must be kept tightly closed and stored in its original packaging.
  • Child Safety: As with all medications, Asmalon must be stored in a secure location out of the sight and reach of children.

Disposal Instructions

Disposal must follow local and national regulations. The preferred method for discarding unused or expired Asmalon is through an official drug take-back program or mail-back envelope. If a take-back option is unavailable, the U.S. FDA recommends mixing the medicine with an undesirable substance (like coffee grounds or kitty litter), placing the mixture in a sealed container, and discarding it in the household trash to avoid environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Asmalon found in:

A-Z Index: